Park Avenue Securities LLC Raises Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Park Avenue Securities LLC boosted its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 28.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 27,651 shares of the company’s stock after buying an additional 6,094 shares during the period. Park Avenue Securities LLC’s holdings in Takeda Pharmaceutical were worth $366,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Versant Capital Management Inc bought a new position in shares of Takeda Pharmaceutical in the 4th quarter worth $26,000. B. Riley Wealth Advisors Inc. bought a new position in Takeda Pharmaceutical in the third quarter worth about $163,000. Franklin Resources Inc. purchased a new stake in shares of Takeda Pharmaceutical during the third quarter valued at about $244,000. Wilmington Savings Fund Society FSB purchased a new position in shares of Takeda Pharmaceutical in the 3rd quarter worth approximately $40,000. Finally, World Investment Advisors LLC bought a new position in shares of Takeda Pharmaceutical during the 3rd quarter worth approximately $258,000. Institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Price Performance

Shares of TAK opened at $12.99 on Friday. The company has a 50 day moving average of $13.32 and a two-hundred day moving average of $13.88. The company has a quick ratio of 0.77, a current ratio of 1.28 and a debt-to-equity ratio of 0.64. Takeda Pharmaceutical Company Limited has a twelve month low of $12.57 and a twelve month high of $15.08. The company has a market cap of $41.32 billion, a price-to-earnings ratio of 22.39, a price-to-earnings-growth ratio of 0.24 and a beta of 0.51.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.